BCH190 The Way We Work With Life
Study Guide Quiz 07, 2006

1. Rheumatoid arthritis is


2. Specialized proteins embedded in cell membranes which receive and transmit chemical messages are often desirable drug targets and are referred to as:


3. Molecules which make the chemical connection between messenger RNA and amino acids during translation are


4. Enzymes are:


5. The flow of information in biological life on earth


6. Different proteins can be distinguished from each other by their


7. RNAi has recently emerged as a new possible therapeutic approach. This technology uses short interfering RNA that are pieces of double-stranded RNA, 21 to 23 nucleotides long, and inhibit translation of specific messenger RNAs. RNAi allows biologists to


8. An approximate time and cost from ‘Bench to Bedside” for the development of a new pharmaceutical product would be in the range of


9. Proteins have the ability to fold into specific shapes that determine their function because of:


10. Proteomics:

11. The stage of protein making in which a messenger-RNA molecule is 'read' by a ribosome is called


12. Stem cells are:


13. Proteins are chains made from reading the sequence of mRNA sequences on a ribosome and linking of amino acids. In 1961 Nirenberg and Mathaei cracked the genetic code with the discovery that


14. Recombinate DNA technology has been able to make what class of compounds as a new class of effective drugs?


15. The study of genome-derived data, including human genetic variation, RNA and protein expression differences, to predict the safety and/or efficacy of drugs in individual patients or groups of patients is called:


16. Actin and myosin interactions cause contraction of


17. Biochips


18. Stem cells have the possibility to be genetically engineered. For example, stem cells could be engineered to express insulin and implanted into the pancreas to become fully functional insulin producing cells. This type of an approach has caused some people to call stem cells


19. What are the implications of gene cloning for the pharmaceutical industry?

20. The ability to replace defective genes in a patient, as a sort of genetic surgery, has not yet been effectively achieved is called